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Abstract	
Histone	methyltransferases	(HMTs)	are	important	epigenetic	regulators	of	gene	transcription	and	are	
disrupted	at	the	genomic	level	in	a	spectrum	of	human	tumors	including	hematological	malignancies.	
Using	high-resolution	SNP-arrays,	we	identified	recurrent	deletions	of	the	SETD2	locus	in	3%	(8/261)	
of	chronic	lymphocytic	leukemia	(CLL)	patients.	Further	validation	in	two	independent	cohorts	showed	
that	SETD2	deletions	were	associated	with	loss	of	TP53,	genomic	complexity	and	chromothripsis.	With	
next	 generation	 sequencing	 we	 detected	 mutations	 of	 SETD2	 in	 an	 additional	 3.8%	 of	 patients	
(23/602).	 In	most	 cases,	SETD2-deletions	or	mutations	were	often	observed	as	a	 clonal	 event	and	
always	 as	 a	 mono-allelic	 lesion,	 leading	 to	 reduced	 mRNA	 expression	 in	 SETD2-disrupted	 cases.	
Patients	with	SETD2	 abnormalities	 and	wild-type	TP53	 and	ATM	 from	 five	 clinical	 trials	 employing	
chemotherapy	 or	 chemo-immunotherapy,	 had	 reduced	 progression-free	 and	 overall	 survival	
compared	 to	 cases	 wild-type	 for	 all	 three	 genes.	 Consistent	 with	 its	 postulated	 role	 as	 a	 tumor	
suppressor,	our	data	highlights	SETD2	aberration	as	a	recurrent,	early	 loss-of-function	event	 in	CLL	
pathobiology	linked	to	aggressive	disease.	
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Introduction	
The	transfer	of	methyl	groups	from	S-adenosyl	methionine	to	lysine	or	arginine	residues	on	histone	
proteins,	 catalyzed	 by	 histone	 methyltransferases	 (HMTs),	 is	 an	 important	 regulator	 of	 gene	
transcription.	 Accordingly,	 HMTs	 are	 disrupted	 by	 various	 mechanisms	 including	 chromosomal	
translocations,	genomic	loss	and/or	point	mutations	in	both	solid	and	hematological	malignancies.1	
Among	the	increasing	number	of	HMT	aberrations	identified	in	human	malignancies,	recurrent	loss	
and/or	inactivating	mutations	of	the	tumor	suppressor	gene	SETD2,	were	initially	identified	in	clear	
cell	 renal	cell	 carcinoma	 (ccRCC)2	and	subsequently	 in	other	solid	 tumors	e.g.	high	grade	gliomas.3	
Moreover,	 SETD2	mutations	 have	 been	 reported	 in	 a	 subset	 of	 patients	with	 acute	 lymphoblastic	
leukemia4	 and	acute	myeloid	 leukemia,	 especially	 those	with	 rearrangements	 in	 the	another	HMT	
gene,	MLL.5	 SETD2	 is	 the	 only	 enzyme	 that	 catalyzes	 the	 trimethylation	 of	 lysine	 36	 on	 histone	 3	
(H3K36me3),	one	of	the	major	chromatin	marks	associated	with	active	transcription.	Recent	studies	
have	 linked	 SETD2	 to	 the	maintenance	of	 genomic	 integrity,	 through	 coordination	of	 homologous	
recombination	repair	after	double	strand	breaks.	The	loss	of	SETD2	impairs	DNA	repair	and	enhances	
genomic	instability,	supporting	its	tumor	suppressor	role.	6-9		
Chronic	 lymphocytic	 leukemia	 (CLL)	 is	characterized	by	remarkable	clinical	heterogeneity	such	that	
some	patients	pursue	an	 indolent	course	while	others	require	early	treatment.	Considerable	effort	
has	focused	on	understanding	the	genetic	diversity	that	underpins	this	clinical	heterogeneity.	High-
resolution	genomic	arrays	and	next-generation	sequencing	have	identified	recurring	novel	regions	of	
genomic	 copy-number	 aberrations	 (CNAs)	 like	 del(13q),	 del(11q),	 trisomy	 12	 and	 del(17p)	 and	
recurrent		driver	mutations	in	genes	such	as	TP53,	ATM,	SF3B1	and	NOTCH1,	respectively	(reviewed	
in	10).	Mutations	frequently	involve	genes	encoding	proteins	with	important	roles	in	cell	signalling,	cell	
cycle	 control,	 DNA	 repair	 and	 RNA-splicing	 and	 processing;	 however	 the	 reported	 incidence	 of	
mutations	in	chromatin	modifiers	is	lower	than	in	many	other	haematological	malignancies.		
In	this	study,	we	report	the	identification	of	recurrent	deletions	and	mutations	of	the	SETD2	gene	in	
large,	 well-characterized	 CLL	 cohorts.	 SETD2	 lesions	 appear	 to	 represent	 early	 events	 in	 CLL	
pathogenesis,	 often	 co-existing	with,	 but	 preceding	 TP53	 abnormalities.	 They	 are	 associated	with	
genomic	complexity	and	chromothripsis,	and	identify	a	subgroup	of	patients	with	poor	outcome.		
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Methods	
Patients	
We	studied	samples	taken	from	1006	CLL	patients	either	at	entry	into	one	of	five	clinical	trials	or	from	
a	cohort	of	untreated	patients	with	progressive	disease	managed	at	the	Royal	Bournemouth	Hospital.	
Four	 randomized	 trials	 (ADMIRE,	 ARCTIC,	 UK	 CLL4	 11,	 GCSG	 CLL8	 12)	 compared	 chemo	 or	 chemo-
immunotherapy	 regimens	 in	 fit	 previously	 untreated	 patients	 while	 the	 fifth	 trial	 (SCSG	 CLL2O)	
enrolled	ultra-high	risk	patients	who	were	either	refractory	to	a	purine	analogue	or	were	previously	
untreated	with	a	17p	deletion.	Further	details	of	the	clinical	trials	are	provided	in	Table	S1.	All	patients	
were	diagnosed	using	standard	morphologic	and	immunophenotypic	criteria.	Informed	consent	was	
obtained	from	all	patients	in	accordance	with	the	Helsinki	declaration,	and	this	study	was	approved	
by	national	or	regional	research	ethics	committees.		
Patients	were	grouped	 into	three	cohorts	(discovery	[n=261],	extension	[n=635]	and	ultra	high-risk	
[n=110]);	 details	 of	 the	 cohort	 composition	 and	 SETD2	 analysis	 are	 summarised	 in	 Table	 1,	
Supplementary	methods	and	Supplementary	figure	1.	DNA	was	extracted	from	CLL	B	cell	samples	(all	
with	>80%	tumour	purity)	and	from	matched	germ-line	DNA	for	SETD2-mutated	cases	as	outlined	in	
Supplementary	methods.	 The	 assessment	of	 established	biomarkers	was	performed	as	 previously	
described.13	572	and	602	samples	were	screened	for	SETD2	loss	and	mutation,	respectively,	with	168	
cases	screened	for	both	loss	and	mutation.	
Genome-wide	microarray-based	copy	number	analysis	
DNA	from	261	discovery	and	110	ultra-high	risk	cases	was	amplified,	labelled	and	hybridized	to	the	
Affymetrix	 SNP6.0	platform,	aligned	onto	 the	human	genome	sequence	 (GRCh37)	and	analysed	 in	
Partek	 Genomics	 Suite	 (Partek	 Inc,	Missouri,	 USA)	 as	 reported	 previously.14-18	 DNA	 from	 201	 pre-
treatment	extension	cases	(ADMIRE	and	ARCTIC)	was	hybridized	to	the	Illumina	HumanOmni1-Quad	
and	 HumanOmniS-8	 platforms	 according	 to	 manufacturer’s	 protocols.	 19,20	 Further	 experimental	
details	are	provides	in	the	Supplementary	methods.		
Targeted	re-sequencing	and	whole	exome	sequencing	
93	CLL	samples	from	the	discovery	cohort	(and	five	matched	germ-line	controls)	were	processed	and	
analysed	for	mutations	in	SETD2	(all	exons)	and	a	number	of	clinically	relevant	genes	with	a	bespoke	
Haloplex	 Target	 Enrichment	 system	 (Agilent	 Technologies)	 (Supplementary	Methods	 Table	 1)	 and	
processed	and	analysed	 as	previously	 reported.21	An	 additional	 231	 cases	 from	our	pre-treatment	
extension	cohort	were	screened	for	SETD2	mutations	using	a	TruSeq	Custom	Amplicon	panel	(Illumina	
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Inc.	San	Diego,	CA,	USA)	as	previously	described.20,22	All	the	variants	identified	by	both	platforms	were	
annotated	against	dbSNP	 (build	135)	and	 functional	prediction	was	also	performed	using	SIFT	and	
Polyphen2	analysis.	 Somatically-acquired	SETD2	mutations	 (n=4)	were	also	 identified	 in	 the	 recent	
whole	exome	sequencing	(WES)	study	of	278	matched	tumor	and	germ-line	cases	from	the	GCSG	CLL8	
study	23.	Additional	experimental	details	are	provided	in	the	Supplementary	methods.	
Sanger	validation	
Variants	 in	 SETD2	 were	 subjected	 to	 validation	 by	 conventional	 Sanger-based	 sequencing	 of	 PCR	
products	obtained	 from	tumor	 [n=11]	and	where	possible,	paired	normal	genomic	DNA	[n=5].	The	
expression	of	SETD2	mutations	at	mRNA	level	was	also	tested	in	samples	with	available	material	[n=4].	
Primers	for	DNA	or	mRNA	validation	are	listed	in	Table	S2.	
Quantitative	RT-PCR	
Total	RNA	was	isolated	from	purified	CLL	cells	of	36	patient	samples	using	RNeasy	columns	(Qiagen)	
and	 reversed	 transcribed	 using	 the	 Improm™II	 RT-PCR	 kit	 (Promega,	 UK)	 according	 to	 the	
manufacturer’s	 instruction.	Primers	and	probes	for	the	housekeeping	genes	(18s)	and	target	genes	
(CCDC12,	 NBEAL2,	 KIF9,	 KLHL18,	 SETD2)	 were	 selected	 using	 the	 Universal	 Probe	 Library	 (Roche	
Applied	Science,	UK)	(Table	S3).	Two	independent	assays	were	designed	to	ascertain	expression	of	3’	
and	5’	SETD2.	Normal	B-cell	mRNA	was	use	to	normalize	the	expression	of	each	gene	by	delta-delta	
CT	method	as	previously	described.24		
Statistical	analysis	
Statistical	analysis	was	performed	with	SPSS	v22.	Differences	between	samples	were	analysed	by	U-
Mann	Whitney	test.	Progression-free	survival	(PFS)	and	overall	survival	(OS)	were	calculated	for	clinical	
trial	 samples	 from	 randomization.	 Survival	 analysis	 was	 performed	 by	 Kaplan-Meier	 and	 log-rank	
analysis.	Significant	differences	were	considered	with	P-values	lower	than	0.05.	
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Results	
Recurrent	deletions	of	3p	are	a	feature	of	CLL	
We	identified	1024	acquired	CNAs	(mean	3.9,	range	0–45)	in	our	discovery	cohort	(Table	S4).	Deletions	
of	chromosome	3p	[del(3p)]	were	observed	in	8	patients	(3%),	ranged	from	0.45-81	Mb	in	size	(Table	
S5),	and	identified	a	well	delineated	MDR	between	genomic	location	46.96-47.39	Mb,	containing	the	
genes	CCDC12,	NBEAL2,	SETD2,	KIF9	and	KLHL18	(Figure	1A).	We	compared	the	expression	of	these	
genes	by	qRT-PCR	in	3p	deleted	[n=6]	versus	non-3p	deleted	patients	[n=8]	(Figure	1C).	We	were	not	
able	to	detect	the	expression	of	KIF9	mRNA	in	CLL	or	normal	B-cells.		Within	the	MDR,	the	HMT	gene	
SETD2	was	 significantly	 under-expressed,	measuring	 by	 two	different	 assays	 targeting	 the	 3’	 or	 5’	
region	of	the	mRNA	(p<0.0001	for	both	assays).		
We	then	aimed	to	confirm	the	presence	of	3p	deletions	and	refine	the	MDR	in	our	extension	cohorts.	
Firstly,	we	identified	nine	del(3p)	cases	(4.5%)	in	our	extension	pre-treatment	cohort,	permitting	the	
MDR	to	be	refined	to	the	SETD2	and	KIF9	loci	(47.12-47.36	Mb,	Figure	1A	and	Table	S5).	Across	our	
discovery	and	pre-treatment	extension	cohorts,	SETD2	deletions	were	present	in	17/461	cases	(3.7%),	
significantly	associated	with	deletions	and/or	mutations	of	TP53	(p=0.003)	and	genomic	complexity	
(≥3	 deletions25,	 p=0.04)(Figure	 1B).	 GISTIC	 2.0	 analysis	 26,	 an	 algorithm	 for	 identifying	 statistically	
significant	regions	of	CNA	above	an	estimated	background	rate	(FDR	q-value	<0.25),	showed	that	in	
39	TP53	 deleted	 cases	 (del(3p),	 n=15),	 the	 SETD2	 region	 on	 3p21.31,	was	 deleted	 at	 a	 significant	
frequency	(q-value=0.001),	ranked	third	after	del(13q)	and	del(17p)	(Figure	S2).		
Interestingly,	 SETD2	 deletions	 without	 concomitant	 TP53/ATM	 abnormalities	 [n=6]	 also	 exhibited	
significantly	more	genomic	complexity	than	wildtype	patients	(p=0.01.	Figure	1D).	Two	SETD2-deleted	
cases	 showed	evidence	of	 chromosome	3	 chromothripsis	 (based	on	>10	CNAs	per	 chromosome18)	
(Figure	1A-B).	In	the	ultra-high	risk	cohort,	SETD2-deletions	were	detected	in	9%	of	cases	[10/110],	
and	were	significantly	enriched	compared	to	the	pre-treatment	cohort	(p=0.009).	All	ten	had	loss	of	
TP53	and	five	had	concomitant	chromosome	3	chromothripsis	(Figure	1B).	To	further	establish	the	
significance	 of	 our	 SETD2	 deletion	 in	 cases	 with	 chromosome	 3	 chromothripsis,	 we	 mapped	 all	
recurrently	3p	deletions	in	these	cases.	This	analysis	showed	that	whilst	additional	regions	of	recurrent	
deletion	were	observed	on	3p,	the	only	regions	shared	across	all	patients	included	the	SETD2	 locus	
(Table	S6).	
We	analysed	SETD2	expression	in	an	extended	cohort	of	patients	with	3p	deletions	[n=16],	and	again	
the	expression	was	diminished	in	these	patients	compared	to	wild-type	patients	(P=0.0068;	Figure	S3).	
In	order	 to	study	 the	clonal	nature	of	 the	SETD2	deletions,	we	assigned	each	genomic	CNA	with	a	
8	
	
relative	copy-number	value	by	normalizing	CNA	 intensity	values	 from	array	 features.	We	excluded	
regions	with	gain	and	sex	chromosome	CNAs	from	the	analysis.	The	cut	off	for	normal	copy	number	
was	established	between	1.7	and	2.3.	We	could	infer	that	the	3p	deletion	was	in	the	dominant	clonal	
population	in	11/18	(61%)	cases	with	data	available	for	analysis	(Figure	S4).	
SETD2	mutations	in	CLL	
To	 identify	 somatic	 gene	mutations,	we	 initially	 employed	 targeted	 re-sequencing	of	 93	discovery	
cohort	cases	and	identified	122	non-silent	mutations	(non-synonymous	n=80,	frameshift	indel	n=20,	
splicing	n=9,	nonframeshift	indel	n=6,	stopgain	n=6,	stoploss	n=1)	targeting	37	genes	in	71/93	cases	
(mean	1.8,	range	1-4).	Sanger	sequencing	confirmed	93.6%	of	the	tested	variants	[n=79],	whilst	the	
remaining	 unconfirmed	 variants	were	 present	 at	 low	 read	 depth	 (n=3)	 or	 in	 a	 low	 percentage	 of	
mutant	reads	(n=2).	We	found	ATM	[n=14],	TP53	[n=14],	NOTCH1	[n=20]	and	SF3B1	[n=15]	mutations	
at	a	frequency	expected	for	the	studied	cohort,	which	aligns	with	published	data	and	demonstrates	
the	validity	of	the	re-sequencing	platform.	We	identified	non-synonymous	SETD2	mutations	in	four	
(4.3%)	discovery	cases	(p.D99G,	p.Q1545K,	p.W1306*,	p.E1955Q)	(Figure	2A-B).	Sanger	sequencing	
validated	 that	 all	 of	 the	 SETD2	 mutations	 were	 present	 in	 tumor	 DNA.	 We	 assessed	 the	 SETD2	
background	mutation	rate,	expression	 level	and	replication	timing	data	from	Lawrence	et	al	27	and	
found	that	the	gene	shares	no	properties	associated	with	false-positive	candidate	cancer	genes.	To	
determine	whether	our	SETD2	mutation	rate	was	indicative	of	over-representation	in	our	CLL	tumours	
we	calculated	 the	nonsynonymous	 -	 synonymous	 ratio	 (Ka/Ks	 ratio)	 for	all	 genes	on	our	discovery	
cohort	targeted	sequencing	gene	panel.	Genes	with	a	Ka/Ks	ratio	greater	than	1	are	under	positive	
selection,	meaning	that	at	least	some	of	the	mutations	are	advantageous	28.	When	ranked	by	Ka/Ks	
ratio	the	SETD2	mutation	rate	is	ranked	sixth	after	ATM,	TP53,	SF3B1,	NOTCH1	and	FAT4	(Table	S7).	
These	ratios	are	frequency	dependant	(SETD2	mutations	are	rare	events),	but	it	is	important	to	state	
that	no	mutated	positions	were	targets	of	synonymous	mutation.	We	obtained	matched	germ-line	
DNA	 from	 three	 patients	 and	 confirmed	 that	 the	 mutations	 were	 somatically	 acquired	 (p.D99G,	
p.W1306*,	p.E1955Q)	(Figure	S5A).	
To	 corroborate	 this	 preliminary	 observation,	 we	 investigated	 231	 cases	 of	 our	 pre-treatment	
extension	 cohort	 by	 TruSeq	 amplicon-based	 sequencing.	 We	 identified	 an	 additional	 nine	 (3.9%)	
SETD2	mutations	(p.A50T,	p.L89F,	p.P167L,	p.N535S,	p.E670K,	p.M1742L,	p.M1889T	(x2),	p.I2295M)	
(Figure	2A-B).	Sanger	sequencing	confirmed	each	SETD2	variant	in	the	tumor	material	and	in	two	cases	
with	germ-line	material	available,	the	variants	were	somatically	acquired.	Assessment	of	WES	data	of	
the	CLL8	study23	samples	included	in	our	pre-treatment	extension	cohort,	revealed	the	presence	of	
somatically-acquired	SETD2	mutations	in	4/278	cases	(1.4%),	namely,	p.EEEELQSQQ1919fs,	p.L1804fs,	
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p.VLEYC1576del,	p.V1190M.	None	of	 these	SETD2	mutations	 (Table	2)	are	annotated	 in	COSMIC29.	
During	the	preparation	of	this	manuscript,	a	study	performed	by	Puente	et	al.	in	506	CLL	patients	also	
described	 both	 SETD2	 mutations	 (0.8%	 of	 cases)	 and	 deletions	 in	 3p	 (2%	 of	 cases)	 whose	 MDR	
encompassed	SETD2	30	whilst	Landau	et	al	identified	SETD2	mutations	in	8/538	(1.5%)	cases	23.	
In	 total,	 across	our	 cohorts	 there	were	15	 somatically-acquired	SETD2	 variants	 (15/602;	2.5%).	An	
additional	eight	variants	that	could	not	be	examined	in	germ-line	material	were	either	absent	(n=3),	
reported	to	have	a	very	low	prevalence	(n=5)	in	1000	Genomes	project	or	have	a	sub-clonal	variant	
allele	frequency	(%VAF	<0.45,	(n=1);	Table	2).	Therefore,	whilst	these	eight	variants	are	predicted	to	
be	functionally	deleterious,	we	cannot	exclude	that	the	minority	may	be	rare	germ-line	variants	as	
they	exhibit	clonal	variant	allele	frequencies	in	the	tumor	material.		
We	were	able	to	confirm	the	expression	of	the	SETD2	mutations	at	mRNA	level	in	four	of	our	patients	
with	available	material	(p.D99G,	p.Q1545K,	p.E1955Q,	p.E670K)	(Figure	S5A),	and	qRT-PCR	analysis	of	
three	SETD2	mutated	samples	showed	that	SETD2	mRNA	expression	was	reduced	compared	to	wild-
type	patients	(P=0.035;	Figure	S3).	
We	performed	integrative	analysis	of	93	cases	from	our	discovery	cohort	with	Haloplex	re-sequencing	
and	 SNP6.0	 copy	 number	 data	 available,	 by	 employing	 the	 ABSOLUTE	 algorithm.31	 This	 approach	
estimates	the	cancer	cell	fraction	(CCF)	harboring	a	given	mutation	by	correcting	for	sample	purity	and	
local	 copy	 number	 changes.	 Mutations	 were	 classified	 as	 clonal	 if	 the	 CCF	 was	 >0.95	 with	 a	
probability	>0.5,	and	sub-clonal	otherwise.32	In	additional	cases	with	proven-somatic	SETD2	mutations	
(n=4)	and	paired	copy	number	data	 from	our	pre-treatment	validation	cohorts,	we	performed	this	
estimation	 by	 manually	 correcting	 for	 tumor	 sample	 purity	 and	 local	 copy-number.	 Our	 analysis	
demonstrated	the	expected	sub-clonal	distribution	of	established	gene	mutations,	such	as	TP53,	ATM,	
SF3B1	and	NOTCH1.	Interestingly,	all	our	somatically	acquired	SETD2	mutations	exhibited	a	clonal	CCF,	
suggesting	that	these	mutations	may	be	early	events	 in	the	evolution	of	CLL	(Figure	2C-D	&	Figure	
S5B-C),	although	further	studies	are	required	to	confirm	this	observation.	
SETD2	aberrations	are	associated	with	inferior	progression	free-	and	overall	survival	
Finally,	we	analysed	the	impact	of	SETD2	abnormalities	(deletion	or	somatically-acquired	mutation)	
on	 progression-free	 (PFS)	 and	 overall	 survival	 (OS)	 in	 front-line	 trial	 patients.	 We	 observed	 a	
significantly	shorter	PFS	in	cases	with	SETD2	abnormalities	that	were	wild-type	for	TP53/ATM	[n=7],	
compared	to	cases	wild-type	for	TP53/ATM/SETD2	 [n=62]	(PFS:	30	vs.	48	months;	p=0.003)	(Figure	
2E).	The	same	patients	with	SETD2	abnormalities	[n=7]	also	had	a	shorter	OS	than	wild-type	patients	
[n=62]	(OS:	34	vs.	92	months;	p<0.001)	(Figure	2F).	Whilst	these	data	suggest	that	SETD2	aberration	
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may	be	clinically	 relevant,	 further	 investigation	 in	 larger	cohorts	 is	needed	to	understand	their	 full	
impact	on	survival.	
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Discussion		
This	study	was	based	on	an	initial	high-resolution	SNP6.0	array	analysis	of	261	untreated	patients	with	
progressive	CLL	which	identified	a	recurrent	deletion	of	the	short	arm	of	chromosome	3	in	3%	of	cases	
(n=8).	The	MDR	included	the	CCDC12,	NBEAL2,	SETD2,	KIF9	and	KLHL18	genes,	of	which	SETD2	was	
the	most	significantly	under-expressed	in	tumor	cells.	We	then	identified	clonal,	somatically-acquired	
SETD2	mutations	in	4.3%	of	this	cohort;	no	mutated	case	had	a	concomitant	SETD2	deletion.		
The	SETD2	gene	encodes	a	230	kDa	protein	that	is	non-redundantly	responsible	for	all	trimethylation	
of	lysine	36	on	histone	H3	(H3K36me3),33,34	a	mark	that	is	associated	with	actively	transcribed	regions	
and	is	involved	in	transcriptional	elongation	and	splicing.	35	In	addition,	recent	studies	have	linked	this	
epigenetic	histone	mark	 to	other	 important	 cellular	processes	 such	as	 the	 regulation	of	mismatch	
repair,	 efficient	 homologous	 recombination	 and	 the	 maintenance	 of	 genomic	 stability.7-9	 In	 vitro	
inhibition	of	Setd2	decreases	global	levels	of	H3K36me3	and	impairs	the	recruitment	of	the	mismatch	
recognition	protein	hMutSα	onto	chromatin,	thereby	preventing	appropriate	DNA	mismatch	repair.	
Cells	 lacking	 the	 Setd2	 protein	 display	 microsatellite	 instability	 and	 have	 elevated	 levels	 of	
spontaneous	 mutations.7,36-38	 Inactivating	 SETD2	 mutations	 were	 first	 described	 in	 ccRCC2,6,	
subsequently	in	other	solid	tumors	such	as	paediatric	high-grade	gliomas	and	most	recently	in	a	subset	
of	 patients	 with	 acute	 lymphoid	 and	 myeloid	 leukemias.	 2,5,39,40	 SETD2	 mutations	 in	 ccRCC	 are	
frequently	associated	with	3p	deletions	resulting	in	loss	of	both	SETD2	and	VHL	genes,	while	in	acute	
leukemias,	SETD2	mutations	may	be	bi-allelic	but	3p	 loss	 is	rare.	SETD2	genomic	abnormalities	are	
associated	 with	 decreased	 H3K36me3	 levels,	 a	 distinctive	 DNA	 methylation	 signature6	 and	
chemoresistance	 in	paediatric	acute	 lymphoblastic	 leukemia	 41.	 In	MLL-rearranged	cells	 from	acute	
leukemic	patients,	Setd2	knockdown	is	implicated	in	disease	initiation	and	progression	by	promoting	
the	self-renewal	capacity	of	leukemic	stem	cells.	
In	view	of	the	role	of	SETD2	disruption	in	tumorigenesis	and	the	identification	of	SETD2	abnormalities	
in	our	discovery	cohort,	we	then	accrued	samples	from	other	patient	cohorts,	including	the	GCLLSG	
CLL8	 cohort	 in	 which	 3p	 deletions	 had	 also	 been	 detected	 18,	 to	 confirm	 the	 incidence	 of	 SETD2	
disruption	and	evaluate	its	biological	and	clinical	consequences	in	CLL.	Previously	untreated	patients	
sampled	at	 randomization	 to	chemo	or	chemo-immunotherapy	 trials	had	a	similar	 incidence	of	3p	
deletions	(4.5%)	to	that	seen	in	the	discovery	cohort	while	a	higher	incidence	of	loss	(9%)	was	found	
in	the	ultra-high	risk	cohort.	The	inclusion	of	additional	cohorts	enabled	a	smaller	MDR	to	be	defined,	
including	 SETD2	 and	 KIF9,	 implicating	 SETD2	 as	 the	 key	 deleted	 gene.	 The	 incidence	 of	 SETD2	
mutations	was	comparable	in	all	cohorts	tested.	The	recent	studies	by	Puente	et	al	and	Landau	et	al,	
published	during	the	preparation	of	this	manuscript	confirms	the	rare	but	recurrent	nature	of	SETD2	
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abnormalities	 23,30.	SETD2	deletions	were	not	over-represented	by	analysis	of	WES	generated	copy	
number	data	in	the	work	by	Landau	and	the	mutation	frequencies	of	both	studies	were	lower	than	
those	 in	our	 study.	The	different	 frequencies	 reported	 in	 these	 two	studies	 could	be	explained	by	
cohort	composition,	as	our	study	included	ultra-high	risk	CLL	and	patients	randomized	to	clinical	trials.	
As	we	found	SETD2	mRNA	expression	to	be	down	regulated	in	cases	with	either	SETD2	deletion	or	
mutations	and	as	we	did	not	observe	bi-allelic	SETD2	abnormalities,	we	assessed	whether	SETD2	may	
also	be	deregulated	by	DNA	methylation.	We	reviewed	the	methylation	status	of	the	SETD2	gene	body	
and	promoter	regions	(15	and	9	CpG	probes,	respectively)	in	the	study	of	Kulis	and	co-workers42	and	
found	no	differential	methylation	levels	between	unmutated	CLL	or	mutated	CLL	or	major	cytogenetic	
sub-types	 (including	 del(17p)	 cases).	 Furthermore,	 SETD2	 mRNA	 expression	 was	 not	 found	 to	 be	
correlated	with	methylation	 status.	 Together,	 this	 suggests	 that	DNA	methylation	does	 not	 play	 a	
substantial	role	in	regulating	SETD2	expression	in	B-CLL	cells,	as	previously	noted	in	acute	leukemia.	
In	addition,	when	we	analysed	SETD2	expression	in	CLL	studies	deposited	in	the	Oncomine	database,43	
we	 observed	 a	 heterogeneous	 pattern.	 Significantly	 reduced	 levels	 are	 evident	 in	 the	minority	 of	
patients,44	which	given	our	observed	association	between	SETD2	deletion	and	expression	could	imply	
gene	deletion	in	those	Oncomine	samples	with	low	mRNA	expression.	
Across	all	cohorts,	SETD2	deletion	was	found	 in	both	 IGHV	mutated	and	unmutated	cases	but	was	
strongly	associated	with	TP53	loss	and	mutation,	likely	accounting	for	its	higher	incidence	in	the	ultra	
-high	risk	cohort.	We	also	noted	an	association	with	genomic	complexity	even	in	cases	lacking	a	TP53	
or	ATM	abnormality,	consistent	with	the	role	of	SETD2	in	maintaining	genomic	stability.	Moreover,	we	
identify	several	SETD2	deletions	that	appeared	to	be	the	result	of	chromothripsis.	The	somatically-
acquired	SETD2	mutations	showed	a	comparable	genomic	distribution	to	those	previously	described	
in	other	tumors	and	were	predicted	to	have	deleterious	functional	consequences.	Furthermore,	their	
association	with	 significantly	 reduced	mRNA	expression	 in	 those	cases	analysed,	 suggest	 that	 they	
either	directly	affect	mRNA	expression,	or	co-exist	with	other	defects	in	transcriptional	control	at	this	
locus.	Interestingly,	we	did	not	observe	a	statistically	significant	association	between	SETD2	mutations	
and	TP53	abnormalities	or	genomic	complexity,	the	implication	of	which	may	be	differing	functional	
consequences	of	mono-allelic	loss	and	mutation.		
In	our	study,	both	SETD2	deletions	and	mutations	often	appeared	to	be	clonal	and	may	precede	TP53	
abnormalities	in	at	least	some	cases.	Setd2	has	been	shown	to	directly	regulate	the	transcription	of	a	
subset	of	genes	via	cooperation	with	the	transcription	factor	p53,45	and	the	link	between	SETD2	and	
TP53	 is	 an	 interesting	 association	 worthy	 of	 functional	 validation.	 It	 is	 possible	 that	 the	 SETD2	
alterations	present	in	our	CLL	cases	may	contribute	to	further	inactivation	of	p53-mediated	checkpoint	
13	
	
control,	a	situation	that	has	been	proposed	in	ccRCC.8	The	low	frequency	of	SETD2	disruption	and	the	
association	 with	 TP53	 abnormalities	 hinder	 an	 accurate	 assessment	 of	 its	 clinical	 consequences.	
Nevertheless,	 we	 observed	 a	 shorter	 PFS	 and	 OS	 in	 patients	 with	 SETD2	 but	 no	 TP53	 or	 ATM	
abnormalities	compared	to	cases	wild	type	for	all	three	genes.	In	support	of	this	preliminary	clinical	
observation,	it	has	been	shown	that	3p	deletions	in	head	and	neck	squamous	carcinoma	(HNSCC)	are	
associated	with	reduced	survival.	46	Furthermore,	the	authors	showed	that	the	co-existence	of	a	TP53	
abnormality	with	del(3p)	decreased	survival	further,	an	observation	that	we	could	not	confirm	in	our	
cohort.	
In	 summary,	 our	 current	 study	 provides	 the	 first	 comprehensive	 analysis	 of	 CNAs	 and	mutations	
targeting	 the	 SETD2	 gene	 in	 a	 large	 cohort	 of	 patients	 with	 CLL.	 We	 find	 somatic	 deletions	 and	
mutations	in	~7%	of	CLL	patients	requiring	treatment.	These	associate	with	TP53	dysfunction,	genomic	
complexity	and	chromothripsis	and	may	be	early	clonal	events.	Functional	studies	are	now	warranted	
to	elucidate	 the	exact	biological	 importance	of	SETD2	 in	CLL	pathogenesis,	but	our	data	adds	 to	a	
growing	body	of	evidence	suggesting	a	role	for	H3K36me3	in	tumorigenesis	that	may	be	exploited	for	
the	development	of	novel	therapeutic	approaches.	
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Figure	1.	SETD2	deletions	in	our	discovery,	extension	and	ultra-high	risk	cohorts	
Figure	1A.	SNP6.0	data	for	the	del(3p)	cases.	Genomic	location	is	indicated	by	the	ladder	to	the	left.	
Each	column	represents	one	patient.	Loss,	gain	and	normal	copy-number	are	shown	as	blue,	red	and	
white,	respectively.	The	black	box	indicates	the	MDR,	and	is	displayed	in	greater	detail	for	our	
discovery	and	extension	cohorts.	The	genes	in	the	MDR	with	their	transcriptional	direction	are	
displayed	in	the	middle,	with	the	MDR	from	the	discovery	and	extension	cohorts	shown	by	the	red	
and	purple	bars,	respectively.	1B.	Matrix	displaying	the	biomarkers	and	genomic	features	associated	
with	del(3p)	cases	with	the	discovery,	extension	and	ultra-high	risk	cases	shown	in	red,	purple	and	
yellow,	respectively.	1C.	Real-time	PCR	expression	for	the	five	genes	localized	in	the	discovery	MDR	
in	cases	with	or	without	del(3p).	All	the	samples	were	negative	for	KIF9.	18s	was	employed	as	
housekeeping	gene.	Expression	in	normal	B-cells	was	used	as	a	normalization	sample.	Mean	±	SD	is	
represented.	1D.	Scatterplots	displaying	the	number	of	CNA	observed	in	subgroups	of	our	cohort	
(excluding	ultra-high	risk	cases).	Cases	were	assigned	to	a	subgroup	using	a	hierarchical	model;	
presence	of	del(17p)	and/or	TP53	mutation,	then	del(11q)	and/or	ATM	mutation,	then	del(3p)	cases	
with	and	without	TP53	abnormalities	and	then	wild-type	(WT)	cases	containing	no	del(17p),	
del(11q),	del(3p)	or	mutations	in	ATM	and	TP53.	Mean	±	SD	is	represented.		
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Figure	2.	SETD2	mutations	in	our	discovery	and	extension	cohorts	
Figure	2A.	Schematic	diagram	of	the	Setd2	protein	with	their	key	functional	domains.	Mutations	are	
displayed	on	the	diagram.	The	colour	denotes	the	cohort,	and	the	filled	circles	are	mutations	that	
have	been	confirmed	as	somatically	acquired.	2B.	Matrix	displaying	the	biomarkers	and	genomic	
features	associated	with	SETD2	mutated	cases	in	the	discovery	(red)	and	extension	(purple)	cases.	
2C.	Analysis	of	the	clonality	for	SETD2	and	other	recurrently	mutated	genes	on	CLL.	For	each	case	
the	cancer	cell	fraction	(CCF)	is	derived	manually	or	with	the	ABSOLUTE	algorithm.	Only	somatically	
acquired	validated	mutations	are	displayed	(cases	69,	100,	S21	and	88).		The	number	of	mutations	
(n)	for	each	gene	in	the	analysis	is	shown	(bottom).	2D.	Percentage	of	cases	harboring	clonal	or	
subclonal	mutations	for	each	of	the	genes	displayed.	2E.	Kaplan-Meier	and	log-rank	analysis	for	
progression-free	survival	(PFS)	in	patients	carrying	SETD2	abnormalities	(“SETD2	ab”)	but	wild-type	
for	TP53	or	ATM	deletion	and/or	mutation	compared	to	those	with	TP53	abnormalities	(“TP53	ab”)	
and	those	wild-type	for	TP53,	ATM	and	SETD2	(“Wild-type”).	2F.	Kaplan-Meier	and	log-rank	analysis	
for	overall	survival	(OS)	in	the	same	categories	described	in	E.
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Table	1	
	
	
Patient	
ID	 SETD2	Mutation	cDNA	change	
SETD2	Mutation	
protein	change	
Functional	prediction	
(Polyphen2;SIFT)	
Somatically	
acquired	validated	 dbSNP	
MAF	1000	
Genomes	
Mutation	
Taster	 Conserved	
Di
sc
ov
er
y	
co
ho
rt
	
69	 c.5863G>C	 p.E1955Q	 P;D	 yes	 rs761536283	 -	 P	 M.Musculus	
100	 c.296A>G	 p.D99G	 -;D	 yes	 -	 -	 M	 M.Musculus	
255	 c.4633C>A	 p.Q1545K	 P;T	 ND	 -	 -	 M	 D.Melano	
S21	 c.3918G>A	 p.W1306*	 D;D	 yes	 -	 -	 M	 G.Gallus	
Ex
te
ns
io
n	
co
ho
rt
		
(in
clu
de
s	C
LL
8	
ca
se
s)
	
149	 c.2008G>A	 p.E670K	 P;D	 yes	 rs374976472	 -	 M	 G.Gallus	
88	 c.5224A>C	 p.M1742L	 P;D	 yes	 -	 - M	 D.Rerio	
4273	 c.148G>A	 p.A50T	 D;D	 ND	 rs191985301	 0.020%	(1/5008)	 P	 M.Musculus	
4530	 c.6885A>G	 p.I2295M	 B;D	 ND	 rs150476239	 0.020%	(1/5008)	 M	 D.Melano	
4546	 c.500C>T	 p.P167L	 B;-	 ND	 rs78682369	 0.020%	(1/5008)	 P	
not	
conserved	
4715	 c.5666T>C	 p.M1889T	 P;D	 ND	 rs148097513	 0.040%	(2/5008)	 M	 G.Gallus	
4172	 c.5666T>C	 p.M1889T	 P;D	 ND	 rs148097513	 0.040%	(2/5008)	 M	 G.Gallus	
4426	 c.1604A>G	 p.N535S	 B;T	 ND	 -	 -	 P	 M.Musculus	
4426	 c.265C>T	 p.L89F	 B,D	 ND	 -	 -	 P	 M.Musculus	
#266	 c.5755-5781delGAAGAGGAAGAATTGCAGTCACAAC	 p.EEEELQSQQ1919fs	 -;-	 yes	 -	 -	 M	 M.Musculus	
#278	 c.5411_5412delAC	 p.L1804fs	 -;-	 yes	 -	 -	 M	 partly	conserved	
#269	 c.4727_4741delTCCTAGAATATTGTG	 p.VLEYC1576del	 -;-	 yes	 -	 -	 M	 M.Musculus	
#313	 c.3568G>A	 p.V1190M	 B;T	 yes	 -	 -	 P	 M.Musculus	
La
nd
au
	e
t	a
l# 	
an
d	
Pu
en
te
	e
t	
al
* 	
#028	 c.6433G>T	 p.G2145*	 -;D	 yes	 -	 -	 M	 M.Musculus	
#065	 c.4973C>G	 p.S1658*	 -;T	 yes	 -	 -	 M	 M.Musculus	
*15	 c.2225C>G	 p.S742*	 -;T	 yes	 -	 -	 M	 partly	conserved	
*#141	 c.6985C>T	 p.Q2329*	 -;T	 yes	 -	 -	 M	 not	conserved	
*#141	 c.7616A>T	 p.K2539I	 D;D	 yes	 -	 -	 M	 M.Musculus	
*177	 c.3876-3877delGT	 p.Y1293fs	 -;-	 yes	 -	 -	 M	 M.Musculus	
Footnote:	ND:	Not	done,	due	to	lack	of	germline	material.	PolyPhen2	prediction	(B	=	Benign;	P	=	Probably	Damaging;	D	=	Damaging;	-	=	No	prediction).	SIFT	prediction	(D	=	Damaging;	T	=	Tolerated;	-	=	No	prediction).	
MAF	(minimal	allele	frequency	in	1000	Genomes	project).	MutationTaster2	prediction	(P=polymorphism;	M=disease	causing).	Underlined	text	indicates	an	AID/APOBEC	recognition	motif.	Mutation	annotation	was	
performed	against	COSMIC	v	73	and	no	overlapping	mutations	were	found.	*Cases	included	in	Puente	et	al	and	#	Landau	et	al.	
